Acerus expands its urology franchise

29 March 2018

Canada’s Acerus Pharmaceuticals (TSX: ASP) has entered into an exclusive distributor and license agreement with USA-based Metuchen Pharmaceuticals, a privately-held specialty pharmaceutical company dedicated to improving men’s health, granting Acerus the exclusive rights to commercialize Stendra (avanafil) in Canada.

Stendra is a new chemical entity targeting the large and growing erectile dysfunction (ED) market. If approved, Stendra, which is already cleared for marketing in the USA, will be one of only two branded PDE5 Inhibitors in Canada.

According to the Canadian Study of Erectile Dysfunction, around 49% of men over 40 suffer from ED, a condition affecting their physical and psychosocial well-being and quality of life. Contemporary treatment focuses on highly-effective, minimally invasive therapies, the most common of which is the PDE5 Inhibitor. The size of the ED market in Canada is estimated at $225 million as of June 2017.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK